FUS错位化重新连接皮质基因网络,以驱动ALS的认知和行为障碍
Raphaelle Cassel1, Félicie Lorenc1, Aurélie Bombardier1
1Université de Strasbourg, Inserm, Strasbourg Translational Neuroscience and Psychiatry, UMR-S1329, Centre de Recherches en Biomédecine; Strasbourg, France.
medRxiv : the preprint server for health sciences
|June 30, 2025
概括
在皮层神经元中错位的FUS蛋白质会在肌缩侧面硬化症 (ALS) 中引起认知和行为问题. 这一发现揭示了ALS认知障碍和行为障碍的新治疗标.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 认知和行为障碍影响到50%的肌缩性侧面硬化症 (ALS) 患者.
- 对于ALS中这些神经缺陷的分子基础在很大程度上是未知的.
研究的目的:
- 为了调查肌缩侧面硬化症 (ALS) 认知和行为障碍的分子起源.
- 确定RNA结合蛋白FUS错位化在ALS相关的神经功能障碍中的作用.
主要方法:
- 在ALS认知障碍患者 (ALS-ci) 的皮质神经元中识别了FUS错位.
- 在皮层投射神经元中利用具有选择性FUS错位化的小鼠模型.
- 执行单核转录组学来分析基因表达变化.
- 研究了FBXO16基因变异在ALS与行为障碍 (ALS-bi) 中的作用.
主要成果:
- 成年皮层神经元中的FUS错位足以诱导ALS-ci和ALS-bi类表型,包括社会缺陷和神经退行.
- 鉴定了一种保存的FUS-依赖基因网络,在小鼠和ALS-ci患者中下调.
- 这一网络对ALS遗传风险因素进行了丰富.
- 削减蛋白质的FBXO16变体与ALS-bi中的行为异常,前缩缩和痴呆症生物标志物有关.
结论:
- 皮层神经元中的FUS错位是驱动ALS认知和行为功能障碍的关键机制.
- FUS-依赖基因网络为ALS神经障碍提供了潜在的治疗点.
- FBXO16在ALS-bi和相关的痴呆症相关生物标志物中涉及新的遗传因素.
相关概念视频
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K
Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678


